Table 2.
Clinical outcomes among the four arms at week 10
| Clinical Outcomes | FMT alone (n = 8) |
R-FMT (n = 9) | CM-FMT (n = 7) | Placebo (n = 11) |
p-value |
|---|---|---|---|---|---|
| Change in IBS-SSS | −32.3 (124.8) | −85.3 (94.6) | −114 (149.3) | −93.4 (97.1) | 0.55 |
| Change in IBS-QoL | 15.4 (20.8) | 19.3 (25.2) | −1.2 (7.6) | 9.4 (18.4) | 0.61 |
| Number with adequate relief | 2 (25%) | 4 (44.4%) | 4 (57.1%) | 4 (36.4%) | 0.66 |
| Number with global improvement |
2 (25%) | 3 (33.3%) | 2 (28.6%) | 2 (18.2%) | 0.95 |
| IBS-SSS Responders | 2 (25%) | 5/8* (62.5%) | 5 (71.4%) | 7 (63.6%) | 0.29 |
| IBS-QoL Responders | 2 (25%) | 2 (22.2%) | 5 (71.4%) | 4 (36.4%) | 0.21 |
Note: Change in score is the difference between week 10 and baseline. A negative value for change in IBS-SSS indicates an improvement in symptoms. A positive value for change in IBS-QoL indicates an improvement in quality of life. *1 patient did not complete IBS-SSS at week 10.